SCHEMBL3585477

SCHEMBL3585477

CCOC(=O)c1cc(Cl)cc(F)c1N

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 11/20 0.52
GAA P10253 10/20 0.52
KDM4E B2RXH2 8/20 0.52
HPGD P15428 7/20 0.52
GLA P06280 6/20 0.52
NPSR1 Q6W5P4 1/20 0.50
HSD17B10 Q99714 2/20 0.45
MAPK1 P28482 2/20 0.44
MAPT P10636 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
TSHR P16473 1/20 0.43
HTT P42858 1/20 0.43
CYP4F2 P78329 1/20 0.42
CYP4A11 Q02928 1/20 0.42
BAZ2B Q9UIF8 1/20 0.42
BAZ2A Q9UIF9 1/20 0.42
POLB P06746 1/20 0.42
ESR2 Q92731 1/20 0.42
MAOB P27338 1/20 0.42
MEN1 O00255 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16529438 0.84 ALDH1A1 (0.55) ALDH1A1GAAKDM4EHPGDGLA
SCHEMBL9727774 0.84 ALDH1A1 (0.71) ALDH1A1GAAKDM4EHPGDGLA
SCHEMBL6948296 0.84 ALDH1A1 (0.55) ALDH1A1GAAKDM4EHPGDGLA
SCHEMBL29264039 0.83 ALDH1A1 (0.54) ALDH1A1GAAKDM4EHPGDGLA
SCHEMBL5409626 0.83 ALDH1A1 (0.54) ALDH1A1GAAKDM4EHPGDGLA
SCHEMBL28892465 0.82 ABL1 (0.51) ALDH1A1GAAKDM4EHPGDGLA
SCHEMBL31373113 0.81 ALDH1A1 (0.39) ALDH1A1GAAKDM4EHPGDGLA
SCHEMBL28825145 0.81 ALDH1A1 (0.53) ALDH1A1GAAKDM4EHPGDGLA
SCHEMBL30361197 0.80 CA1 (0.52) ALDH1A1GAAKDM4EHPGDGLA
SCHEMBL26466636 0.80 CA1 (0.52) ALDH1A1GAAKDM4EHPGDGLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1984340-B1 ANTHRANILAMIDE/2-AMINO-HETEROARENE CARBOXAMIDE DERIVATIVES HOFFMANN LA ROCHE (CH) 2012-06-27 EP disclosed
US-7678818-B2 Anthranilamide and 2-amino-heteroarene-carboxamide compounds HOFFMANN-LA ROCHE INC. (US) 2010-03-16 US disclosed
EP-1984340-A1 ANTHRANILAMIDE/2-AMINO-HETEROARENE CARBOXAMIDE DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2008-10-29 EP disclosed
US-20070219261-A1 Anthranilamide and 2-amino-heteroarene-carboxamide compounds HOFFMANN-LA ROCHE INC. 2007-09-20 US disclosed
WO-2007090752-A1 ANTHRANILAMIDE/2-AMINO-HETEROARENE CARBOXAMIDE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2007-08-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070219261-A1 Anthranilamide and 2-amino-heteroarene-carboxamide compounds AADAT, AAAS, AADAC ALDH1A1 1414/4885GAA 450/4885KDM4E 1828/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.